Key Points
- Insider sale: Todd Watanabe sold 4,375 Arcutis shares for $114,275 under a pre-arranged Rule 10b5-1 plan to cover tax withholding. The sale reduced his position by 0.61% and appears administrative rather than a bearish signal.
- Strong quarterly results: Arcutis reported $129.86 million in revenue and $0.11 in adjusted earnings per share, exceeding analysts’ expectations. The company also raised its 2026 net product sales outlook to $525 million–$540 million.
- Positive growth outlook: FDA approvals and regulatory progress for expanded ZORYVE uses, including pediatric psoriasis and potential infant atopic dermatitis treatment, add to the company’s growth opportunities. Analysts have a “Moderate Buy” consensus rating with a $34 average price target.
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) insider Patrick Burnett sold 955 shares of the company's stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $26.12, for a total value of $24,944.60. Following the completion of the transaction, the insider directly owned 119,289 shares in the company, valued at $3,115,828.68. The trade was a 0.79% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Patrick Burnett also recently made the following trade(s):
- On Monday, May 11th, Patrick Burnett sold 222 shares of Arcutis Biotherapeutics stock. The stock was sold at an average price of $21.05, for a total value of $4,673.10.
Arcutis Biotherapeutics Stock Performance
ARQT opened at $27.10 on Thursday. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.68 and a quick ratio of 2.46. The business has a fifty day simple moving average of $25.87 and a 200 day simple moving average of $24.68. Arcutis Biotherapeutics, Inc. has a 1 year low of $13.69 and a 1 year high of $31.77. The company has a market capitalization of $3.39 billion, a PE ratio of -903.03 and a beta of 1.49.
Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.05. Arcutis Biotherapeutics had a negative return on equity of 1.41% and a negative net margin of 0.57%.The firm had revenue of $129.86 million for the quarter, compared to analysts' expectations of $118.85 million. Research analysts expect that Arcutis Biotherapeutics, Inc. will post 0.16 EPS for the current year.
Institutional Investors Weigh In On Arcutis Biotherapeutics
Hedge funds have recently modified their holdings of the company. UBS Group AG grew its stake in Arcutis Biotherapeutics by 10.0% during the fourth quarter. UBS Group AG now owns 3,243,432 shares of the company's stock worth $94,189,000 after purchasing an additional 294,994 shares during the period. Tudor Investment Corp ET AL bought a new position in shares of Arcutis Biotherapeutics during the third quarter valued at about $1,319,000. Kornitzer Capital Management Inc. KS boosted its holdings in Arcutis Biotherapeutics by 55.1% during the first quarter. Kornitzer Capital Management Inc. KS now owns 175,870 shares of the company's stock worth $4,143,000 after purchasing an additional 62,485 shares during the last quarter. Vanguard Group Inc. grew its position in Arcutis Biotherapeutics by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 7,253,936 shares of the company's stock worth $210,654,000 after purchasing an additional 107,846 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund bought a new position in shares of Arcutis Biotherapeutics during the 4th quarter worth approximately $26,136,000.
Wall Street Analysts Forecast Growth
ARQT has been the topic of several recent research reports. Wall Street Zen raised shares of Arcutis Biotherapeutics from a "hold" rating to a "buy" rating in a report on Sunday, July 12th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Arcutis Biotherapeutics in a report on Wednesday, June 24th. Finally, Needham & Company LLC reissued a "buy" rating and set a $36.00 price target on shares of Arcutis Biotherapeutics in a report on Thursday, May 7th. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Arcutis Biotherapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $34.00.
View Our Latest Stock Analysis on ARQT
Key Headlines Impacting Arcutis Biotherapeutics
Here are the key news stories impacting Arcutis Biotherapeutics this week:
- Positive Sentiment: Strong revenue growth and earnings beat: Second-quarter net product revenue reached $129.9 million, up 59% from the prior-year quarter and 23% sequentially. Adjusted earnings of $0.11 per share exceeded analyst estimates ranging from $0.06 to $0.09, compared with a $0.13 loss a year earlier. Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update
- Positive Sentiment: Raised 2026 sales outlook: Arcutis increased its full-year net product sales guidance to $525 million–$540 million, signaling confidence in sustained demand for ZORYVE. The company also maintained positive operating cash flow during the quarter. Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update
- Positive Sentiment: Expanded growth opportunities: The FDA approved ZORYVE cream 0.3% for plaque psoriasis in children as young as two. The FDA also accepted an application for use in infants aged three to 24 months with mild-to-moderate atopic dermatitis, with a target decision date of February 23, 2027. Enrollment is complete in a Phase 2 vitiligo study, with results expected in the fourth quarter of 2026. Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update
- Neutral Sentiment: Insider sales appear administrative: Three executives sold a combined 6,560 shares at approximately $26.12 per share. The transactions were made under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards, limiting their significance as a bearish signal. SEC Insider Trading Filing
Arcutis Biotherapeutics Company Profile
(
Get Free Report)
Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company's research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.
In August 2022, Arcutis received U.S.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
